BC Week In Review | Jan 12, 2018
Company News

Shire to split neuro and rare disease businesses

Shire plc (LSE:SHP; NASDAQ:SHPG) said it will split its neuroscience and rare disease businesses into two divisions. The separation comes after the pharma said in its 2Q17 earnings report that it was evaluating options for...
BC Extra | Jan 9, 2018
Company News

Shire splits neuro and rare disease businesses

Shire plc (LSE:SHP; NASDAQ:SHPG) said it will split its neuroscience and rare disease businesses into two divisions. The separation comes after the pharma said in its 2Q17 earnings report that it was evaluating options for...
BC Week In Review | Aug 4, 2017
Company News

Shire evaluating neurology pipeline

In its 2Q17 earnings report, Shire plc (LSE:SHP; NASDAQ:SHPG) said it will evaluate options for its neurology franchise, with the potential of spinning out the company’s core ADHD business into an independent public company. The...
BC Extra | Aug 3, 2017
Company News

Shire evaluating neurology pipeline

In its 2Q17 earnings report, Shire plc (LSE:SHP; NASDAQ:SHPG) said it will evaluate options for its neurology franchise, with the potential of spinning out the company’s core ADHD business into an independent public company. The...
BC Week In Review | May 23, 2016
Company News

Neos Therapeutics sales and marketing update

Neos launched once-daily Adzenys XR-ODT amphetamine in the U.S. to treat ADHD in patients ages six and older. The wholesale acquisition cost (WAC) of a 3.1, 6.3, 9.4, 12.5, 15.7 or 18.8 mg tablet is...
BC Week In Review | Feb 1, 2016
Clinical News

Adzenys XR-ODT amphetamine regulatory update

FDA approved an NDA from Neos for Adzenys XR-ODT amphetamine to treat ADHD in patients ages >=6. Neos plans to launch the drug next quarter. The extended-release, orally disintegrating tablet formulation of amphetamine polistirex uses...
BC Extra | Jan 29, 2016
Company News

Neos rises after ADHD approval

Neos Therapeutics Inc. (NASDAQ:NEOS) gained $3.96 (42%) to $13.38 on Thursday after FDA approved Adzenys XR-ODT ( NT-0202 ) to treat ADHD in patients aged six and older. Chief Commercial Officer Thomas McDonnell said Neos expects to...
BC Week In Review | Sep 7, 2015
Clinical News

Amphetamine XR-ODT regulatory update

Neos resubmitted an NDA to FDA for NT-0202 to treat ADHD. Neos expects the agency to designate the NDA as a Class 2 resubmission, with a 6-month review. The extended-release, orally disintegrating tablet formulation of...
BC Week In Review | Nov 24, 2014
Company News

Shire pharmaceuticals news

Shire will pay $56.5 million to settle civil investigation of its sales and marketing practices for ulcerative colitis drugs Pentasa mesalamine and Lialda mesalamine. Shire will also pay $2.9 million to resolve allegations over its...
BC Week In Review | Oct 20, 2014
Company News

Shire, Neos Therapeutics deal

Shire granted Neos a non-exclusive license to market Neos' amphetamine polistirex XR-ODT ( NT-0202 ) for ADHD in the U.S. The deal settles litigation filed by Shire in April 2013 in the U.S. District Court for the...
Items per page:
1 - 10 of 242